{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:31:59Z","timestamp":1786361519426,"version":"build-2736575974"},"reference-count":38,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Carlos Chagas Institute, Oswaldo Cruz Foundation","award":["VPPIS-004-FIO-22-2-20"],"award-info":[{"award-number":["VPPIS-004-FIO-22-2-20"]}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","award":["402251\/2023-7"],"award-info":[{"award-number":["402251\/2023-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"award":["402251\/2023-7"],"award-info":[{"award-number":["402251\/2023-7"]}],"id":[{"id":"https:\/\/ror.org\/03swz6y49","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide, largely because it is diagnosed late. Diagnosis typically relies on imaging and biopsy, but only after tumors have advanced, which reduces treatment effectiveness. Current biochemical biomarkers are limited to CA19-9, which is more useful for prognosis and monitoring than for diagnosis. Circulating miRNAs may offer minimally invasive complementary biomarkers for PDAC diagnosis, potentially accounting for ethnic and treatment-related variables. We performed small RNA sequencing on plasma from five non-metastatic-stage and five metastatic-stage PDAC patients and 10 healthy controls to generate an exploratory miRNA profile. Candidate miRNAs were then validated by RT-qPCR in an independent cohort of 70 PDAC patients and 106 healthy controls, and nine miRNAs showed promising differential plasma expression. Notably, miRNA484 and miRNA335-5p were associated with PDAC in CA19-9-negative patients, with ROC AUCs of 0.984 and 0.88, respectively. Overall, these results indicate that miRNA484 and miRNA335-5p may have clinical value as complementary biomarkers for PDAC patients who are CA19-9-negative.<\/jats:p>","DOI":"10.3390\/biom16081160","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:23:50Z","timestamp":1786357430000},"page":"1160","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["miRNA484 and miRNA335-5p as Potential Diagnostic Biomarkers for CA19-9-Negative Pancreatic Ductal Adenocarcinoma"],"prefix":"10.3390","volume":"16","author":[{"given":"Nayra Oliveira","family":"Prado","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Oncology, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba 81310-020, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2260-7949","authenticated-orcid":false,"given":"Anelis Maria","family":"Marin","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Oncology, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba 81310-020, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Zem","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Oncology, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba 81310-020, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheli","family":"de Marchi","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Oncology, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba 81310-020, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9652-5184","authenticated-orcid":false,"given":"Diogo Dias","family":"Ara\u00fajo","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Oncology (LIM24), Instituto do Cancer do Estado de S\u00e3o Paulo (ICESP), Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo (HCFMUSP), S\u00e3o Paulo 01246-000, Brazil"},{"name":"Comprehensive Center for Precision Oncology (C2PO), Universidade de S\u00e3o Paulo, S\u00e3o Paulo 01246-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9 Ferreira","family":"Alves","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Oncology (LIM24), Instituto do Cancer do Estado de S\u00e3o Paulo (ICESP), Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo (HCFMUSP), S\u00e3o Paulo 01246-000, Brazil"},{"name":"Comprehensive Center for Precision Oncology (C2PO), Universidade de S\u00e3o Paulo, S\u00e3o Paulo 01246-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2589-6432","authenticated-orcid":false,"given":"Miyuki","family":"Uno","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Oncology (LIM24), Instituto do Cancer do Estado de S\u00e3o Paulo (ICESP), Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo (HCFMUSP), S\u00e3o Paulo 01246-000, Brazil"},{"name":"Comprehensive Center for Precision Oncology (C2PO), Universidade de S\u00e3o Paulo, S\u00e3o Paulo 01246-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0342-8726","authenticated-orcid":false,"given":"Roger","family":"Chammas","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Oncology (LIM24), Instituto do Cancer do Estado de S\u00e3o Paulo (ICESP), Hospital das Cl\u00ednicas da Faculdade de Medicina da Universidade de S\u00e3o Paulo (HCFMUSP), S\u00e3o Paulo 01246-000, Brazil"},{"name":"Comprehensive Center for Precision Oncology (C2PO), Universidade de S\u00e3o Paulo, S\u00e3o Paulo 01246-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9397-4127","authenticated-orcid":false,"given":"Dalila Luc\u00edola","family":"Zanette","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Oncology, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba 81310-020, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5166-2897","authenticated-orcid":false,"given":"Mateus N\u00f3brega","family":"Aoki","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Oncology, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba 81310-020, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"ref_1","unstructured":"(2026, April 05). International Agency for Research on Cancer Cancer Today. Available online: https:\/\/gco.iarc.who.int\/today\/en\/dataviz\/tables?mode=population&cancers=13&types=1."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic Cancer: Advances and Challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"ref_3","unstructured":"(2026, April 05). National Cancer Institute Cancer Stat Facts: Pancreatic Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12029-025-01183-2","article-title":"Trends in the Global Incidence of Pancreatic Cancer and a Brief Review of Its Histologic and Molecular Subtypes","volume":"56","author":"Leiphrakpam","year":"2025","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Brancato, L., Osok, D., Van den Bossche, L., Van Cutsem, E., Bates, S.E., Van den Bossche, J., and Bogers, J. (2025). CA19-9 as a Dynamic Biomarker for Continuous Monitoring of Therapeutic Efficacy in Pancreatic Adenocarcinoma. Cancers, 17.","DOI":"10.3390\/cancers17243902"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"217245","DOI":"10.1016\/j.canlet.2024.217245","article-title":"A Rigorous Multi-Laboratory Study of Known PDAC Biomarkers Identifies Increased Sensitivity and Specificity over CA19-9 Alone","volume":"604","author":"Haab","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_7","first-page":"340","article-title":"The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates","volume":"13","author":"Poruk","year":"2013","journal-title":"Curr. Mol. Med."},{"key":"ref_8","first-page":"105","article-title":"The Clinical Utility of Serum CA 19-9 in the Diagnosis, Prognosis and Management of Pancreatic Adenocarcinoma: An Evidence Based Appraisal","volume":"3","author":"Ballehaninna","year":"2012","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Pian, L.L., Song, M.H., Wang, T.F., Qi, L., Peng, T.L., and Xie, K.P. (2025). Identification and Analysis of Pancreatic Intraepithelial Neoplasia: Opportunities and Challenges. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1401829"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10585-023-10256-0","article-title":"miRNAs in Pancreatic Cancer Progression and Metastasis","volume":"41","author":"Mok","year":"2024","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"111914","DOI":"10.1016\/j.biopha.2021.111914","article-title":"Emerging Roles of miRNAs in the Development of Pancreatic Cancer","volume":"141","author":"Fathi","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Daoud, A.Z., Mulholland, E.J., Cole, G., and McCarthy, H.O. (2019). MiRNAs in Pancreatic Cancer: Biomarkers, Prognostic, and Therapeutic Modulators. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6284-y"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A New Mathematical Model for Relative Quantification in Real-Time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.3748\/wjg.v27.i26.4045","article-title":"Biomarkers in the Diagnosis of Pancreatic Cancer: Are We Closer to Finding the Golden Ticket?","volume":"27","author":"Stoita","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Primavesi, F. (2021). Clinical Presentation and Symptoms in Pancreatic Cancer. Textbook of Pancreatic Cancer: Principles and Practice of Surgical Oncology, Springer.","DOI":"10.1007\/978-3-030-53786-9_24"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Truong, L.H., and Pauklin, S. (2021). Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches. Cancers, 13.","DOI":"10.3390\/cancers13195028"},{"key":"ref_17","first-page":"680","article-title":"MiRNA in Carcinogenesis & Cancer Diagnostics: A New Paradigm","volume":"137","author":"Ahmad","year":"2013","journal-title":"Indian J. Med. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13046-020-01570-6","article-title":"Exosomal miRNAs in Tumor Microenvironment","volume":"39","author":"Tan","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41544-019-0014-0","article-title":"Extracellular and Intracellular miRNAs in Pancreatic Cancer: From Early Diagnosis to Reducing Chemoresistance","volume":"1","author":"Jiang","year":"2019","journal-title":"ExRNA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.beem.2016.10.001","article-title":"MicroRNAs in the Thyroid","volume":"30","author":"Boufraqech","year":"2016","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_21","first-page":"6496570","article-title":"MiRNAs as Biomarkers in Thyroid Carcinoma","volume":"2017","author":"Celano","year":"2017","journal-title":"Int. J. Genom."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Park, J.L., Kim, S.K., Jeon, S., Jung, C.K., and Kim, Y.S. (2021). MiRNA Profile for Diagnostic and Prognostic Biomarkers in Thyroid Cancer. Cancers, 13.","DOI":"10.3390\/cancers13040632"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chhatriya, B., Mukherjee, M., Ray, S., Sarkar, P., Chatterjee, S., Nath, D., Das, K., and Goswami, S. (2019). Comparison of Tumour and Serum Specific miRNA Changes Dissecting Their Role in Pancreatic Ductal Adenocarcinoma: A Meta-Analysis. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6380-z"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Xu, X., Bhandari, K., Xu, C., Morris, K., and Ding, W.Q. (2023). miRNA18a and miRNA106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087215"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.gastha.2024.08.002","article-title":"Blood-Based miRNA Biomarker Signature of Early-Stage Pancreatic Ductal Adenocarcinoma with Lead-Time Trajectory in Prediagnostic Samples","volume":"3","author":"Treekitkarnmongkol","year":"2024","journal-title":"Gastro Hep Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jcp.25056","article-title":"MiRNA as Biomarkers and Diagnostics","volume":"231","author":"Wang","year":"2016","journal-title":"J. Cell. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1423-0127-19-90","article-title":"Dysregulation of MiRNAs in Cancer","volume":"19","author":"Chen","year":"2012","journal-title":"J. Biomed. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/gm516","article-title":"MiRNAs and the Cancer Phenotype: Profiling, Signatures and Clinical Implications","volume":"5","author":"Stahlhut","year":"2013","journal-title":"Genome Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"F19","DOI":"10.1677\/ERC-09-0184","article-title":"The Role of Let-7 in Cell Differentiation and Cancer","volume":"17","author":"Boyerinas","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Makler, A., and Asghar, W. (2023). Exosomal miRNA Biomarker Panel for Pancreatic Ductal Adenocarcinoma Detection in Patient Plasma: A Pilot Study. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065081"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40364-017-0087-6","article-title":"Tissue MiRNA Profiles as Diagnostic and Prognostic Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma and Periampullary Cancers","volume":"5","author":"Calatayud","year":"2017","journal-title":"Biomark. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101847","DOI":"10.1016\/j.tranon.2023.101847","article-title":"Diagnostic Plasma Small Extracellular Vesicles miRNA Signatures for Pancreatic Cancer Using Machine Learning Methods","volume":"40","author":"Pu","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ijc.30790","article-title":"Plasma miRNAs as Biomarkers of Pancreatic Cancer Risk in a Prospective Cohort Study","volume":"141","author":"Duell","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kim, K., Yoo, D., Lee, H.S., Lee, K.J., Park, S.B., Kim, C., Jo, J.H., Jung, D.E., and Song, S.Y. (2019). Identification of Potential Biomarkers for Diagnosis of Pancreatic and Biliary Tract Cancers by Sequencing of Serum miRNAs. BMC Med. Genom., 12.","DOI":"10.1186\/s12920-019-0521-8"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3892\/ol.2016.4955","article-title":"Role of Yes-Associated Protein in Cancer: An Update","volume":"12","author":"Abylkassov","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"106980","DOI":"10.1016\/j.phrs.2023.106980","article-title":"Identification of Exosomal miRNA484 Role in Reprogramming Mitochondrial Metabolism in Pancreatic Cancer through Wnt\/MAPK Axis Control","volume":"197","author":"Lin","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1158\/1078-0432.CCR-19-0674","article-title":"lncRNA THAP9-AS1 Promotes Pancreatic Ductal Adenocarcinoma Growth and Leads to a Poor Clinical Outcome via Sponging miR-484 and Interacting with YAP","volume":"26","author":"Li","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.1007\/s13277-014-2092-9","article-title":"MiRNA335 Functions as a Tumor Suppressor in Pancreatic Cancer by Targeting OCT4","volume":"35","author":"Gao","year":"2014","journal-title":"Tumour Biol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/8\/1160\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:58:10Z","timestamp":1786359490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/8\/1160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["biom16081160"],"URL":"https:\/\/doi.org\/10.3390\/biom16081160","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]}}}